NEW YORK, Feb. 25 - Paradigm Genetics and researchers at the Duke University Medical Center have signed a multi-year research collaboration that seeks to apply metabolomics to drug discovery and development, Paradigm said on Monday.
Terms of the agreement call for Paradigm and the DUMC initially to research cardiovascular disease to identify and validate drug targets and to hunt for new biomarkers that may be used in predictive medicine. Studies are set to begin this quarter.
The research, which will extend beyond cardiovascular disease as the collaboration moves ahead, will bring together cardiology researchers at the university with Paradigm's metabolomics platform, MetaVantage.
"By bringing together [DUMC's] cardiologists with our ... experts in metabolomics, we believe we will identify new and better ways to diagnose and treat cardiovascular disease," John A. Ryals, Paradigm Genetics' president and CEO, said in a statement.